Paper505347
Tuberculin reactivity as a predictor of survival time in inoperable bronchial carcinoma.
Snell NJ. Thorax, 1979. Cited by 4 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Tuberculin reactivity as a predictor of survival time in inoperable bronchial carcinoma. Papers, record 505347. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/505347
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bronchial Neoplasms | Major topic |
| Tuberculin Test | Major topic |
| Aged | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Prognosis | |
| Retrospective Studies |
Source PubMed
References9
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 831755 | Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. | Br J Cancer | 1977 | https://conductscience.org/library/papers/831755 | PubMed |
| 2 | 1088260 | Impaired lymphocyte responses to PPD-tuberculin in advanced breast carcinoma. Increased reactivity after depletion of phagocytic or adherent cells. | Clin Oncol | 1976 | https://conductscience.org/library/papers/1088260 | PubMed |
| 3 | 5093257 | Diagnosis of lung cancer in tuberculous patients. Use of tuberculin skin test and serum protein electrophoresis. | Chest | 1971 | https://conductscience.org/library/papers/5093257 | PubMed |
| 4 | 4336426 | Relationship between tumor doubling time and anatomoclinical features in 50 measurable pulmonary cancers. | Chest | 1972 | https://conductscience.org/library/papers/4336426 | PubMed |
| 5 | 4354467 | Prognosis of early bronchogenic carcinoma. Survival curves of 451 patients after resection of lung cancer in relation to the results of pre-operative tuberculin skin test. | Biomedicine | 1973 | https://conductscience.org/library/papers/4354467 | PubMed |
| 6 | 941299 | An assessment of the carcinogenicity of isoniazid in patients with pulmonary tuberculosis. | Tubercle | 1976 | https://conductscience.org/library/papers/941299 | PubMed |
| 7 | 5726401 | [Contribution to the study of phenomena of cellular immunity in pulmonary cancer before palliative or surgical treatment]. | Poumon Coeur | 1968 | https://conductscience.org/library/papers/5726401 | PubMed |
| 8 | 5643759 | Immunologic alterations in bronchogenic cancer. Sequential study. | Cancer | 1968 | https://conductscience.org/library/papers/5643759 | PubMed |
| 9 | 5848663 | Suppression of the tuberculin response in malignant disease. | Br Med J | 1965 | https://conductscience.org/library/papers/5848663 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 7314014 | In vitro monocyte maturation as a prediction of survival in squamous cell carcinoma of the lung. | Thorax | 1981 | https://conductscience.org/library/papers/7314014 | PubMed |
| 6285089 | The management of lung cancer. | Lung | 1982 | https://conductscience.org/library/papers/6285089 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/505347
GET https://conductscience.org/api/papers/v1/505347/authors